Compare ADMA Biologics Inc (ADMA) vs Msci Inc (MSCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Msci Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Msci Inc trades at $601.06 (market cap $44.27B). The key difference: Msci Inc is far larger — about 20.8× ADMA Biologics Inc's market cap, and Msci Inc pays a 1.35% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MSCI | |
|---|---|---|
Market Cap | $2.13B | $44.27B |
Sector | Health | Financials |
52-Week High | $20.38 | $643.83 |
52-Week Low | $7.60 | $511.84 |
Enterprise Value | $2.20B | $50.43B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MSCI trades at $608.09, up 0.83% with a bullish technical outlook and strong fundamental performance. The company delivered three consecutive quarterly earnings beats, maintains exceptional profit margins above 40%, and shows consistent revenue growth. Recent strategic acquisitions and AI integration initiatives position MSCI for continued market leadership in financial analytics and index services.
With 69% analyst buy ratings and a $700.50 consensus price target representing 15% upside, MSCI offers growth potential despite premium valuations. Key risks include high debt levels and market classification decisions impacting revenue streams. The stock's current technical setup near pivot point $606 suggests potential for continued upward momentum if earnings momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
